{"organizations": [], "uuid": "228581be5321817fb741611b2bceb534f125c7eb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-pfizer-doses-first-patient-using-i/brief-pfizer-doses-first-patient-using-investigational-mini-dystrophin-gene-therapy-for-the-treatment-of-duchenne-muscular-dystrophy-idUSFWN1RP0KL", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfizer Doses First Patient Using Investigational Mini Dystrophin Gene Therapy For The Treatment Of Duchenne Muscular Dystrophy", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-12T15:02:00.000+03:00", "replies_count": 0, "uuid": "228581be5321817fb741611b2bceb534f125c7eb"}, "author": "", "url": "https://www.reuters.com/article/brief-pfizer-doses-first-patient-using-i/brief-pfizer-doses-first-patient-using-investigational-mini-dystrophin-gene-therapy-for-the-treatment-of-duchenne-muscular-dystrophy-idUSFWN1RP0KL", "ord_in_thread": 0, "title": "BRIEF-Pfizer Doses First Patient Using Investigational Mini Dystrophin Gene Therapy For The Treatment Of Duchenne Muscular Dystrophy", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "pfizer inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "treatment of duchenne muscular dystrophy reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12, 2018 / 12:04 PM / Updated 8 minutes ago BRIEF-Pfizer Doses First Patient Using Investigational Mini Dystrophin Gene Therapy For The Treatment Of Duchenne Muscular Dystrophy Reuters Staff \nApril 12 (Reuters) - Pfizer Inc: \n* DYSTROPHIN GENE THERAPY FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY \n* DYSTROPHIN GENE THERAPY STUDY TRIAL ARE EXPECTED IN FIRST HALF OF 2019 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-12T15:02:00.000+03:00", "crawled": "2018-04-12T15:18:03.000+03:00", "highlightTitle": ""}